Madathil Arjun Kolappurath, Ghaskadbi Saroj, Kalamkar Saurabh, Goel Pranay
Biology Division, Indian Institute of Science Education and Research, Pune, India.
Department of Zoology, Savitribai Phule Pune University, Pune, India.
Front Pharmacol. 2023 Mar 13;14:1139673. doi: 10.3389/fphar.2023.1139673. eCollection 2023.
Oral GSH supplementation along with antidiabetic treatment was shown to restore the body stores of GSH significantly and reduce oxidative DNA damage (8-OHdG) in Indian Type 2 diabetic (T2D) patients over 6 months in our recent clinical study. Post hoc analysis of the data also suggested that elder patients benefit from improved HbA1c and fasting insulin. We modeled longitudinal changes in diabetic individuals using a linear mixed-effects (LME) framework and obtained i) the distribution of individual trajectories with and without GSH supplementation and ii) the overall rates of changes in the different study arms. Serial changes in elder and younger diabetic individuals were also modeled independently to examine differences in their progression. The average linear trajectories obtained from the model explain how biochemical parameters in T2D patients progress over 6 months on GSH supplementation. Model estimates show improvements in erythrocytic GSH of 108 µM per month and a reduction in 8-OHdG at a rate of 18.5 ng/μg DNA per month in T2D patients. GSH replenishes faster in younger people than in the elder. 8-OHdG reduced more rapidly in the elder (24 ng/μg DNA per month) than in younger (12 ng/μg DNA per month) individuals. Interestingly, elder individuals show a substantial reduction in HbA1c (0.1% per month) and increased fasting insulin (0.6 µU/mL per month). Changes in GSH correlate strongly with changes in HbA1c, 8-OHdG, and fasting insulin in the elder cohort. The model estimates strongly suggest it improves the rate of replenishment in erythrocytic GSH stores and reduces oxidative DNA damage. Elder and younger T2D patients respond differently to GSH supplementation: It improves the rate of reduction in HbA1c and increases fasting insulin in elder patients. These model forecasts have clinical implications that aid in personalizing treatment targets for using oral GSH as adjuvant therapy in diabetes.
在我们最近的一项临床研究中,对印度2型糖尿病(T2D)患者进行了为期6个月的观察,结果显示,在接受抗糖尿病治疗的同时口服补充谷胱甘肽(GSH),可显著恢复机体GSH储备,并减少氧化DNA损伤(8-羟基脱氧鸟苷,8-OHdG)。对数据的事后分析还表明,老年患者的糖化血红蛋白(HbA1c)和空腹胰岛素水平有所改善。我们使用线性混合效应(LME)框架对糖尿病个体的纵向变化进行建模,得到了:i)补充和不补充GSH情况下个体轨迹的分布;ii)不同研究组的总体变化率。我们还分别对老年和年轻糖尿病个体的系列变化进行建模,以研究他们病情进展的差异。该模型得出的平均线性轨迹解释了T2D患者在补充GSH的6个月内生化参数的变化情况。模型估计显示,T2D患者红细胞内GSH每月增加108µM,8-OHdG每月以18.5 ng/μg DNA的速率减少。年轻人GSH的补充速度比老年人快。8-OHdG在老年人中减少得更快(每月24 ng/μg DNA),而在年轻人中则为每月12 ng/μg DNA。有趣的是,老年个体的HbA1c大幅降低(每月0.1%),空腹胰岛素水平升高(每月0.6µU/mL)。在老年队列中,GSH的变化与HbA1c、8-OHdG和空腹胰岛素的变化密切相关。模型估计强烈表明,它提高了红细胞GSH储备的补充率,并减少了氧化DNA损伤。老年和年轻T2D患者对补充GSH的反应不同:它提高了老年患者HbA1c的降低率,并增加了空腹胰岛素水平。这些模型预测具有临床意义,有助于为在糖尿病治疗中使用口服GSH作为辅助治疗制定个性化的治疗目标。